Indication DUPIXENT is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

RAPID AND SUSTAINED RELIEF OF
SYMPTOMS AND IMPROVED QoL,
as measured by snot-22

Significantly decreased SNOT-22 score vs placebo as early as Week 4, with continued improvement at Weeks 24 and 52 (secondary endpoint)1,a

SNOT-22 score reduction through week 52 IN trial 2
59%
Improvement

with DUPIXENT (baseline score 50.16) vs 17% improvement with placebo (baseline score 53.48) (LSM difference: -20.96 [95% CI: -25.03, -16.89])

  • DUPIXENT 300 mg Q2W + INCS (n=150)
  • Placebo + INCS (n=153)
  • 54% improvement at Week 24 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) (-27.77 from a baseline score of 51.02) vs 19% improvement with placebo + INCS (n=153) (-10.40 from a baseline score of 53.48) (LSM difference: -17.36 [95% CI: -20.87, -13.85]) in Trial 21
  • 39% improvement seen as early as Week 4 with DUPIXENT Q2W + INCS (n=295, pooled DUPIXENT arms) (-19.77 from a baseline score of 51.02) vs 16% improvement with placebo + INCS (n=153) (-8.35 from a baseline score of 53.48) (LSM difference: -11.41 [95% CI: -14.78, -8.05]) in Trial 21

TURN TO DUPIXENT TO IMPROVE A RANGE OF CRSwNP SYMPTOMS AND QoL MEASURES2

  • 22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0 to 110): reduced score indicates improvement.
  • aSNOT-22 includes 22 items assessing symptoms and symptom impact associated with CRSwNP. SNOT-22 had a 2-week recall period. The meaningful clinically important difference is 8.9.
  • CRSwNP, chronic rhinosinusitis with nasal polyposis; INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks; QoL, quality of life.

Identify CRSwNP
patients appropriate
for DUPIXENT

View Patients

References:

  1. Data on file, Sanofi US. LIBERTY NP SINUS-52, CSR. 2018.
  2. DUPIXENT Prescribing Information.